Long‐term amyloid PET and MRI outcomes in a menopausal hormone therapy trial

20260 citationsJournal Articlehybrid Open Access

Authors

Kejal Kantarci · Mayo Clinic

Firat Kara · Mayo Clinic

Nirubol Tosakulwong · Mayo Clinic in Florida

Angela J. Fought · Mayo Clinic in Florida

Christopher G Schwarz · Mayo Clinic

Matthew L. Senjem · Mayo Clinic

June Kendall-Thomas ·

Abstract

NCT00154180 Kronos Early Estrogen Prevention Study (KEEPS) HIGHLIGHTS: There were no menopausal hormone therapy-related adverse effects or benefits on amyloid beta and magnetic resonance imaging biomarkers in the long term. Apolipoprotein E ε4 carrier status did not modify these findings. Findings align with neutral cognitive and cerebrovascular outcomes in this cohort.

Topics & Keywords

Dementia and Cognitive Impairment Research Menopause: Health Impacts and Treatments Cancer-related cognitive impairment studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Alzheimer s & Dementia

Volume 22, Issue 2, pp. e71067-e71067

DOI: 10.1002/alz.71067

Field-Weighted Citation Impact: 0.00